Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology · Corticotroph Tumor Progression After Bilateral Adrenalectomy

Understanding Pituitary Growth After Adrenal Surgery (Nelson Syndrome)

At a Glance

Nelson syndrome is pituitary tumor growth that can occur after both adrenal glands are removed for Cushing disease. Loss of cortisol feedback may drive growth, so regular MRI scans, ACTH hormone tests, and clinical visits are important even without symptoms.

Bilateral adrenalectomy is often a life-changing surgery that successfully resolves the high cortisol levels of Cushing disease [1]. However, for many patients, removing the adrenal glands is not the end of the journey. First, it causes lifelong adrenal insufficiency requiring prescribed glucocorticoid replacement. Second, once the adrenal glands are gone, the body no longer produces cortisol, which previously acted as a “brake” on the pituitary gland. Without this brake, the pituitary tumor that originally caused the Cushing disease can begin to grow again [2].

This growth was historically called Nelson syndrome. Today, medical specialists often use a more descriptive name: Corticotroph Tumor Progression after Bilateral Adrenalectomy (CTP-BADX) [1][3]. It is important to understand that this progression is not a failure of your surgery or a sign that the operation was inadequate; it is a recognized but variable risk that your care team will monitor for years to come [4].

Why the Tumor May Grow

The pituitary gland and the adrenal glands normally work in a “feedback loop.” The pituitary sends out a hormone called ACTH (adrenocorticotropic hormone), which tells the adrenal glands to make cortisol. In a healthy loop, once cortisol levels rise, they signal the pituitary to slow down.

In Cushing disease, a pituitary tumor ignores these signals and pumps out too much ACTH. When both adrenal glands are removed (bilateral adrenalectomy), the source of cortisol is gone. This “loss of negative feedback” means there is nothing left to restrain the tumor cells [2]. While this loss of cortisol is the primary trigger, research shows that some tumors are also naturally more aggressive due to their own genetic makeup, which may explain why some grow faster than others [5][6].

How Common Is Progression?

Because modern imaging is so much more sensitive than the tools used decades ago, doctors now identify tumor progression much more frequently. It is estimated that roughly 30% to 50% of patients will show signs of tumor growth within 10 years after their adrenal surgery [6][4].

  • Registry Data: In the European Registry on Cushing’s Syndrome (ERCUSYN), approximately 45% of patients followed after adrenalectomy developed progression [4].
  • Timeframes: While it can happen as early as two months after surgery, the risk continues over time. In some studies, the risk of radiographic progression was 27% at three years, rising to 54% at ten years [7][4].
  • Radiographic vs. Clinical: Many patients have “radiographic progression”—meaning the tumor grows slightly on an MRI—without ever feeling any symptoms. In one study cohort, over half of the patients showed growth on an MRI, but only about 30% of those eventually required further treatment like surgery or radiation [8].

Shifting Definitions: From Nelson’s to CTP-BADX

The way doctors talk about this condition has changed significantly as technology has improved, though the terms are not perfectly interchangeable.

Feature Historical “Nelson Syndrome” Modern “CTP-BADX”
Primary Indicator Hyperpigmentation (skin darkening) and extremely high ACTH [3]. MRI Evidence showing a new or enlarging tumor [1].
Diagnosis Often diagnosed only after symptoms were severe [9]. Diagnosed early through routine, scheduled monitoring [1].
Focus The “triad” of skin changes, high ACTH, and a known tumor [9]. Early detection of growth to prevent vision loss or other complications [7].

Monitoring and Long-Term Care

Because the risk of progression is an expected part of life after a bilateral adrenalectomy, international guidelines recommend a monitoring framework to catch changes early [1]. This schedule should be individualized based on your own risks.

  1. Baseline MRI: Usually performed 3 months after your adrenal surgery [1].
  2. Early Monitoring: An MRI every 12 months for the first 3 years [1].
  3. Long-term Surveillance: If the tumor remains stable, MRIs may be spaced out to every 2 to 4 years, but you will still need an annual clinical check-up with your endocrinologist [1].
  4. ACTH Tracking: Your doctor will likely measure your early-morning ACTH levels regularly. A rapid rise in ACTH can be associated with an active tumor and requires closer attention [10][5].

The goal of this monitoring is to ensure that if growth does occur, it is managed before it can affect your vision or press on other critical structures in the brain [11]. While the idea of continued tumor growth is daunting, being proactive with your follow-up appointments is the most effective way to protect your long-term health.

Common questions in this guide

What does Nelson syndrome mean after adrenal surgery?
Nelson syndrome is growth or enlargement of the ACTH-producing pituitary tumor that caused Cushing disease after both adrenal glands have been removed. The newer term is corticotroph tumor progression after bilateral adrenalectomy, or CTP-BADX. It is a recognized risk after surgery and does not mean the adrenalectomy failed.
How common is pituitary tumor growth after bilateral adrenalectomy?
Studies estimate that about 30% to 50% of patients show tumor progression within 10 years, although estimates vary with follow-up and imaging sensitivity. MRI growth may be small and cause no symptoms, and not everyone with radiographic growth needs another treatment.
How often should I have MRI scans and ACTH tests after adrenalectomy?
Guidelines commonly suggest a baseline pituitary MRI about three months after surgery, yearly MRI scans for the first three years, and scans every two to four years if the tumor remains stable. An endocrinologist may also check early-morning ACTH regularly and should tailor the schedule to your risks and results.
Does a rising ACTH level prove that Nelson syndrome is progressing?
A rapid rise in early-morning ACTH can be a warning that the tumor is active, but an ACTH result alone does not show whether the tumor has enlarged. Doctors interpret the blood test together with MRI findings, symptoms, and other clinical information.
What symptoms of pituitary tumor growth should I report?
New or worsening skin darkening, especially on the knuckles, scars, or gums, may be a sign of high ACTH. Report changes in side vision, other vision problems, or more frequent headaches promptly, because a growing tumor can affect structures involved in sight.
Can Nelson syndrome be treated if the tumor grows?
If MRI shows meaningful growth or the tumor threatens vision or nearby brain structures, the care team may consider pituitary surgery or radiation therapy. The best approach depends on tumor size, location, growth rate, prior treatment, and overall health.
Why do I need glucocorticoid replacement after bilateral adrenalectomy?
After both adrenal glands are removed, the body cannot make enough cortisol, so lifelong prescribed glucocorticoid replacement is required. This replacement treats adrenal insufficiency but does not control pituitary tumor growth; your care team should provide dosing and illness instructions.

Get notified when new evidence is published on Nelson syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

    Reincke M, Albani A, Assie G, et al.

    European journal of endocrinology 2021; (184(3)):P1-P16.

    PMID: 33444221
  2. 2

    The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.

    Fukuoka H, Shichi H, Yamamoto M, Takahashi Y

    International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239132.

    PMID: 33266265
  3. 3

    Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies.

    Patel J, Eloy JA, Liu JK

    Neurosurgical focus 2015; (38(2)):E14 doi:10.3171/2014.10.FOCUS14681.

    PMID: 25639316
  4. 4

    Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.

    Valassi E, Castinetti F, Ferriere A, et al.

    Endocrine-related cancer 2022; (29(12)):681-691 doi:10.1530/ERC-22-0074.

    PMID: 36197784
  5. 5

    Corticotroph tumor progression speed after adrenalectomy.

    Bessiène L, Moutel S, Lataud M, et al.

    European journal of endocrinology 2022; (187(6)):797-807 doi:10.1530/EJE-22-0536.

    PMID: 36206174
  6. 6

    From Nelson's Syndrome to Corticotroph Tumor Progression Speed: An Update.

    Bessiène L, Villa C, Bertagna X, et al.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2024; (132(10)):581-590 doi:10.1055/a-2359-8649.

    PMID: 38959959
  7. 7

    Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis.

    Papakokkinou E, Piasecka M, Carlsen HK, et al.

    Pituitary 2021; (24(5)):797-809 doi:10.1007/s11102-021-01158-z.

    PMID: 34036460
  8. 8

    Characterizing and predicting the Nelson-Salassa syndrome.

    Graffeo CS, Perry A, Carlstrom LP, et al.

    Journal of neurosurgery 2017; (127(6)):1277-1287.

    PMID: 28084914
  9. 9

    Nelson's Syndrome: An Update.

    Fountas A, Karavitaki N

    Endocrinology and metabolism clinics of North America 2020; (49(3)):413-432 doi:10.1016/j.ecl.2020.05.004.

    PMID: 32741480
  10. 10

    ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome.

    Das L, Bhansali A, Pivonello R, et al.

    Pituitary 2020; (23(5)):488-497 doi:10.1007/s11102-020-01047-x.

    PMID: 32449103
  11. 11

    Nelson's Syndrome: A Narrative Review.

    Torres-Ríos JA, Romero-Luna G, Meraz Soto JM, et al.

    Cureus 2023; (15(5)):e39114 doi:10.7759/cureus.39114.

    PMID: 37332454

This page explains Nelson syndrome and follow-up after bilateral adrenalectomy for informational purposes only and does not constitute medical advice. Your endocrinology team should interpret your ACTH results, MRI findings, and need for treatment.